Literature DB >> 19713161

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models.

Anna Bergamaschi1, Geir Olav Hjortland, Tiziana Triulzi, Therese Sørlie, Hilde Johnsen, Anne Hansen Ree, Hege Giercksky Russnes, Sigurd Tronnes, Gunhild M Maelandsmo, Oystein Fodstad, Anne-Lise Borresen-Dale, Olav Engebraaten.   

Abstract

The number of relevant and well-characterized cell lines and xenograft models for studying human breast cancer are few, and may represent a limitation for this field of research. With the aim of developing new breast cancer model systems for in vivo studies of hormone dependent and independent tumor growth, progression and invasion, and for in vivo experimental therapy studies, we collected primary mammary tumor specimens from patients, and implanted them in immunodeficient mice. Primary tumor tissue from 29 patients with breast cancer was implanted subcutaneously with matrigel in SCID mice, in the presence of continuous release of estradiol. The tumors were transferred into new animals when reaching a diameter of 15mm and engrafted tumors were harvested for morphological and molecular characterization from passage six. Further, gene expression profiling was performed using Agilent Human Whole Genome Oligo Microarrays, as well as DNA copy number analysis using Agilent Human Genome CGH 244K Microarrays. Of the 30 primary tumors implanted into mice (including two implants from the same patient), two gave rise to viable tumors beyond passage ten. One showed high expression levels of estrogen receptor-alpha protein (ER) while the other was negative. Histopathological evaluation of xenograft tumors was carried out at passage 10-12; both xenografts maintained the morphological characteristics of the original tumors (classified as invasive grade III ductal carcinomas). The genomic profile of the ER-positive xenograft tumor resembled the profile of the primary tumor, while the profile obtained from the ER-negative parental tumor was different from the xenograft. However, the ER-negative parental tumor and xenograft clustered on the same branch using unsupervised hierarchical clustering analysis on RNA microarray expression data of "intrinsic genes". A significant variation was observed in the expression of extracellular matrix (ECM)-related genes, which were found downregulated in the engrafted tumors compared to the primary tumor. By IHC and qRT-PCR we found that the downregulation of stroma-related genes was compensated by the overexpression of such molecules by the mouse host tissue. The two established breast cancer xenograft models showed different histopathological characteristics and profound diversity in gene expression patterns that in part can be associated to their ER status and here described as basal-like and luminal-like phenotype, respectively. These two new breast cancer xenografts represent useful preclinical tools for developing and testing of new therapies and improving our knowledge on breast cancer biology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19713161      PMCID: PMC5527532          DOI: 10.1016/j.molonc.2009.07.003

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  23 in total

1.  CGH-Explorer: a program for analysis of array-CGH data.

Authors:  Ole Christian Lingjaerde; Lars O Baumbusch; Knut Liestøl; Ingrid K Glad; Anne-Lise Børresen-Dale
Journal:  Bioinformatics       Date:  2004-11-05       Impact factor: 6.937

2.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.

Authors:  Anna Bergamaschi; Young H Kim; Pei Wang; Therese Sørlie; Tina Hernandez-Boussard; Per E Lonning; Robert Tibshirani; Anne-Lise Børresen-Dale; Jonathan R Pollack
Journal:  Genes Chromosomes Cancer       Date:  2006-11       Impact factor: 5.006

3.  Genomic sequencing.

Authors:  G M Church; W Gilbert
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

6.  Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.

Authors:  S Geisler; P E Lønning; T Aas; H Johnsen; O Fluge; D F Haugen; J R Lillehaug; L A Akslen; A L Børresen-Dale
Journal:  Cancer Res       Date:  2001-03-15       Impact factor: 12.701

Review 7.  Triple-negative breast cancer: risk factors to potential targets.

Authors:  Bryan P Schneider; Eric P Winer; William D Foulkes; Judy Garber; Charles M Perou; Andrea Richardson; George W Sledge; Lisa A Carey
Journal:  Clin Cancer Res       Date:  2008-12-15       Impact factor: 12.531

8.  Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.

Authors:  A Bergamaschi; E Tagliabue; T Sørlie; B Naume; T Triulzi; R Orlandi; H G Russnes; J M Nesland; R Tammi; P Auvinen; V-M Kosma; S Ménard; A-L Børresen-Dale
Journal:  J Pathol       Date:  2008-02       Impact factor: 7.996

9.  A new model of patient tumor-derived breast cancer xenografts for preclinical assays.

Authors:  Elisabetta Marangoni; Anne Vincent-Salomon; Nathalie Auger; Armelle Degeorges; Franck Assayag; Patricia de Cremoux; Ludmilla de Plater; Charlotte Guyader; Gonzague De Pinieux; Jean-Gabriel Judde; Magali Rebucci; Carine Tran-Perennou; Xavier Sastre-Garau; Brigitte Sigal-Zafrani; Olivier Delattre; Véronique Diéras; Marie-France Poupon
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

Review 10.  Stromal fibroblasts in cancer initiation and progression.

Authors:  Neil A Bhowmick; Eric G Neilson; Harold L Moses
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

View more
  50 in total

1.  Generation of a Liver Orthotopic Human Uveal Melanoma Xenograft Platform in Immunodeficient Mice.

Authors:  Ken Kageyama; Shinji Ozaki; Takami Sato
Journal:  J Vis Exp       Date:  2019-11-06       Impact factor: 1.355

Review 2.  Epigenetic regulation of EMT: the Snail story.

Authors:  Yiwei Lin; Chenfang Dong; Binhua P Zhou
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 3.  Patient-Derived Xenograft Models in Breast Cancer Research.

Authors:  Deukchae Na; Hyeong-Gon Moon
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics.

Authors:  Mike Mattie; Ashley Christensen; Mi Sook Chang; William Yeh; Suzanne Said; Yuriy Shostak; Linnette Capo; Alla Verlinsky; Zili An; Ingrid Joseph; Yi Zhang; Sathish Kumar-Ganesan; Karen Morrison; David Stover; Pia Challita-Eid
Journal:  Neoplasia       Date:  2013-10       Impact factor: 5.715

Review 5.  Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.

Authors:  Shawna B Matthews; Carol A Sartorius
Journal:  Horm Cancer       Date:  2016-10-28       Impact factor: 3.869

6.  Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.

Authors:  Peter Kabos; Jessica Finlay-Schultz; Chunling Li; Enos Kline; Christina Finlayson; Joshua Wisell; Christopher A Manuel; Susan M Edgerton; J Chuck Harrell; Anthony Elias; Carol A Sartorius
Journal:  Breast Cancer Res Treat       Date:  2012-07-24       Impact factor: 4.872

7.  Subtype-specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts.

Authors:  Eldrid Borgan; Evita M Lindholm; Siver Moestue; Gunhild M Mælandsmo; Ole Christian Lingjærde; Ingrid S Gribbestad; Anne-Lise Børresen-Dale; Olav Engebraaten; Therese Sørlie
Journal:  Mol Oncol       Date:  2012-10-23       Impact factor: 6.603

8.  Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance.

Authors:  Li Zhang; Yoshitsugu Mitani; Carlos Caulin; Pulivarthi H Rao; Merrill S Kies; Pierre Saintigny; Nianxiang Zhang; Randal S Weber; Scott M Lippman; Adel K El-Naggar
Journal:  Am J Pathol       Date:  2013-04-10       Impact factor: 4.307

9.  Patient-derived xenografts recapitulate molecular features of human uveal melanomas.

Authors:  Cécile Laurent; David Gentien; Sophie Piperno-Neumann; Fariba Némati; André Nicolas; Bruno Tesson; Laurence Desjardins; Pascale Mariani; Audrey Rapinat; Xavier Sastre-Garau; Jérôme Couturier; Philippe Hupé; Leanne de Koning; Thierry Dubois; Sergio Roman-Roman; Marc-Henri Stern; Emmanuel Barillot; J William Harbour; Simon Saule; Didier Decaudin
Journal:  Mol Oncol       Date:  2013-02-26       Impact factor: 6.603

10.  Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations.

Authors:  Evita M Lindholm; Marit Krohn; Sergio Iadevaia; Alexandr Kristian; Gordon B Mills; Gunhild M Mælandsmo; Olav Engebraaten
Journal:  Clin Cancer Res       Date:  2013-11-05       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.